RECRUITING

Single Blinded First CMC Osteoarthritis Treatment

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Single blinded PRP vs. Corticosteroid vs. Placebo (normal saline) intra-articular injection for basal joint arthritis.

Official Title

Randomized Single Blinded First CMC Osteoarthritis Treatment: Therapy and Bracing Alone vs. Intra-Articular Corticosteroid Injection vs Intra-Articular Leukocyte Depleted Platelet Rich Plasma

Quick Facts

Study Start:2018-09-01

Study Completion:2025-03-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03196310

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Stage 1-3 osteoarthritis of the basal joint	* Patients with Stage 4 1st carpometacarpal joint arthritis as described by Eaton * Patients who have received a corticosteroid injection in the last year to the 1st CMC joint on the proposed study side * Patients who have scaphotriquetral, radioscaphoid, or scaphotrapezial osteoarthritis * Patients who have concurrent DeQuervain's tenosynovitis or intersection syndrome or have been treated for either of these in the last 3 months * Patients undergoing evaluation of cervical radiculopathy * Patients with fibromyalgia or inflammatory rheumatic disease * Patients with Pressier disease, Kienbock's, or avascular necrosis of the scaphoid * Patients with any history of primary or secondary bone tumor * Patients that are pregnant or terminally ill

Inclusion Criteria

Exclusion Criteria

* Stage 1-3 osteoarthritis of the basal joint

* Patients with Stage 4 1st carpometacarpal joint arthritis as described by Eaton
* Patients who have received a corticosteroid injection in the last year to the 1st CMC joint on the proposed study side
* Patients who have scaphotriquetral, radioscaphoid, or scaphotrapezial osteoarthritis
* Patients who have concurrent DeQuervain's tenosynovitis or intersection syndrome or have been treated for either of these in the last 3 months
* Patients undergoing evaluation of cervical radiculopathy
* Patients with fibromyalgia or inflammatory rheumatic disease
* Patients with Pressier disease, Kienbock's, or avascular necrosis of the scaphoid
* Patients with any history of primary or secondary bone tumor
* Patients that are pregnant or terminally ill

Contacts and Locations

Study Contact

Naem Mufarreh

CONTACT

937-298-4331

naem.mufarreh@ketteringhealth.org

Study Locations (Sites)

Orthopedic Associates of Southwest Ohio

Centerville, Ohio, 45459

United States

Collaborators and Investigators

Sponsor: Kettering Health Network

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-09-01

Study Completion Date2025-03-31

Study Record Updates

Study Start Date2018-09-01

Study Completion Date2025-03-31

Terms related to this study

Additional Relevant MeSH Terms

Osteoarthritis Thumb